1. Barnett Banks, Inc., Jacksonville, Florida; to *de novo* in making, acquiring, and servicing loans pursuant to § 225.25(b)(1) of the Board's Regulation Y.

D. Federal Reserve Bank of Chicago (David S. Epstein, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. First Midwest Bancorp, Naperville, Illinois; to engage *de novo* in making and servicing loans pursuant to § 225.25(b)(1) of the Board's Regulation Y. These activities will be conducted in Danville, Illinois; Moline, Illinois; Plainfield, Illinois, and Waukegan, Illinois.

E. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. Security Bank Shares, Inc., Iron River, Wisconsin; to engage *de novo* in making and servicing loans pursuant to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, April 2, 1992.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 92-8011 Filed 4-7-92; 8:45 am]

BILLING CODE 6210-01-F

Ann McKeel Ross; Change in Bank Control Notice; Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than April 30, 1992.

A. Federal Reserve Bank of Atlanta (Robert E. Heck, Vice President) 104 Marietta Street, NW., Atlanta, Georgia 30303:

1. Ann McKeel Ross, Temple Terrace, Florida; to acquire 2.70 percent of the voting shares of The Terrace Bank of Florida, Tampa, Florida.

Board of Governors of the Federal Reserve System, April 2, 1992.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 92-8012 Filed 4-7-92; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Solicitation of Nominations for Membership on the U.S. Advisory Board on Child Abuse and Neglect

AGENCY: Administration for Children and Families (ACF) HHS.

ACTION: Notice of solicitation of nominations for membership on the U.S. Advisory Board for Child Abuse and Neglect.

SUMMARY: Section 102(b) of the Child Abuse Prevention and Treatment Act, (Public Law 100-294, provides that the Secretary shall appoint members to the Advisory Board on Child Abuse and Neglect. This notice solicits nominations for appointment to the Board, sets procedures for submission and receipt of nominations, and provides information concerning the membership, duties and responsibilities of the Board.

DATES: Nominations must be received by May 8, 1992.

ADDRESSES: Nomination must be in writing and submitted as follows: Assistant Secretary for Children and Families, 370 L'Enfant Promenade, SW., suite 600, Washington, DC 20447.

FOR FURTHER INFORMATION CONTACT: Megan Hedden, Special Assistant, Administration for Children and Families, (202) 401-2337.

SUPPLEMENTARY INFORMATION:

A. Background

The U.S. Advisory Board on Child Abuse and Neglect (the Board) was established under provisions of Public Law 100-294, which reenacted the Child Abuse Prevention and Treatment Act (the Act). The Board came into existence on May 30, 1989. Section 102(b) of the Act requires the Secretary to publish a notice in the **Federal Register** soliciting nominations for the appointment of members from the general public to the Board.

The Act specifies the composition of the Board, the number of members, professional and other areas of expertise, terms of office, meeting duties, and compensation of members. This information is provided below in order to solicit the nomination of five highly qualified persons to the Board.

Any changes to the nomination process and/or the Board's composition, responsibilities and compensation which result from the likelihood that the U.S. Congress will enact new authorizing legislation will be implemented as appropriate.

B. Composition of the Board

The Board consists of 15 members appointed by the Secretary, 13 from the general public and two from the Federal Government. In making all the appointments from the general public, the Secretary is required by the Act to give due consideration to representation of ethnic or racial minorities and diverse geographic areas.

C. Representation on the Board

The public members of the Board must be knowledgeable in child abuse and neglect prevention, intervention, treatment, or research, and must represent the following areas:

(1) Law (including the judiciary);
(2) Psychology (including child development);
(3) Social services (including child protective services);
(4) Medicine (including pediatrics);
(5) State and local government;
(6) Organizations providing services to persons with disabilities;
(7) Organizations providing services to adolescents;
(8) Teachers;
(9) Parent self-help organizations;
(10) Parents' groups; and
(11) Voluntary groups.

D. Terms of Office

The length of the terms to which persons from the general public are appointed is four years, except for appointments to complete the balance of terms of members who resigned prior to the expiration of their term. Once appointed, a person from the general public may be reappointed to an additional consecutive term and may be reappointed to non-consecutive terms without limit at the discretion of the Secretary.

E. Meetings

The Board meets a minimum of two times per year. The duration of each meeting is usually four days. To date, the Board has held ten meetings. Much of the Board's work is completed by conference calls.

F. Duties of the Board

1. The Board must annually submit to the Secretary and the appropriate

Committees of the Congress a report containing:

(a) Recommendations on coordinating Federal child abuse and neglect activities to prevent duplication and ensure efficient allocations of resources and program effectiveness; and

(b) Recommendations for carrying out the purposes of the Act.

2. The Board must annually submit to the Secretary and the Director of the National Center on Child Abuse and Neglect a report containing long-term and short-term recommendations on:

(a) Programs;

(b) Research;

(c) Grant and contract needs;

(d) Areas of unmet needs; and

(e) Areas to which the Secretary should provide grant and contract priorities under the Act's research and demonstration authorities.

3. The Board must annually review the budget of the National Center on Child Abuse and Neglect and submit to the Director a report concerning each review.

In addition, the Board holds hearings, conducts symposia, and issues special reports and position papers.

G. Compensation

1. Except as provided in paragraph (3), members of the Board, other than those regularly employed by the Federal government, while serving on business of the Board may receive compensation at the rate not in excess of the daily equivalent payable to a GS–18 employee under section 5332 of title 5, United States Code, including travel time.

2. Except as provided in paragraph (3), members of the Board, while serving on business of the Board away from their homes or regulator places of business, may be allowed travel expenses (including per diem in lieu of subsistence) as authorized by section 5703 of title 5, United States Code, for persons in the Government service employed intermittently.

3. The Director may not compensate a member of the Board under this section if the member is receiving compensation or travel expenses from another source while serving on business of the Board.

H. Nominations

At this time the Department is soliciting nominations for five members possessing specific expertise in child maltreatment. We required also representation of expertise in one of the following areas: elementary or secondary school teaching, State and local government, parents' groups, and voluntary groups; as well as other areas. The term of the seat for the person with expertise in elementary or secondary school teaching will expire on May 29, 1995. Terms for the other seats will expire on May 29, 1996. Nominations must be in writing and must include biographical information, vitae, address and telephone number of the nominee, as well as a brief description of relevant information to fulfill the required areas of expertise stated above and under sections B and C of this notice and to successfully execute the responsibilities of a member of the Board. Two references from persons with personal knowledge of the nominee's expertise in the field of child maltreatment and in any of the specific categories of representation must also be included. The same individual may be nominated for a seat in more than one category. Nominations may be made for one's self or for someone else.

Dated: March 28, 1992.

Jo Anne B. Barnhardt,

Assistant Secretary for Children and Families.

[FR Doc. 92–7980 Filed 4–7–92; 8:45 am]

BILLING CODE 4130–01–M

Food and Drug Administration

[Docket No. 92F–0117]

Hoechst Aktiengesellschaft; Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Hoechst Aktiengesellschaft has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a mixture of methylated 4,4'-bis (2-benzoxazolyl) stilbenes, with the major portion consisting of 4-(2-benzoxazolyl)-4'-(5-methyl-2-benzoxazolyl) stilbene and lesser portions consisting and 4,4'-bis (2-benzoxazolyl) stilbene, as an optical brightener in all food-contact polymers.

FOR FURTHER INFORMATION CONTACT: Helen R. Thorsheim, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St., SW., Washington, DC 20204, 202–254–9511.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(B)(5))), notice is given that a petition (FAP 2B4317) has been filed by Hoechst Aktiengesellschaft, c/o 1001 G St., NW., suite 500 West, Washington, DC 20001. The petition proposes to amend the food additive regulations in § 178.3297 *Colorants for polymers* (21 CFR 178.3297) to provide for the safe use of a mixture of methylated 4,4'-bis(2-benzoxazolyl) stilbenes, with the major portion consisting of 4-(2-benzoxazolyl)-4'-(5-methyl-2-benzoxazolyl) stilbene and lesser portions consisting of 4,4'-bis (5-methyl-2-benzoxazolyl) stilbene and 4,4'-bis (2-benzoxazolyl) stilbene, as an optical brightener in all food contact polymers.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 31, 1992.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92–8029 Filed 4–7–92; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 92F–0111]

Lubrizol Corp.; Filing of Food Additive Petitions

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that The Lubrizol Corp. has filed three petitions proposing that the food additive regulations be amended to provide for the safe use of poly(sodium 2-acrylamido-2-methylpropanesulfonate) in adhesives and as components of paper and paperboard intended to contact food.

FOR FURTHER INFORMATION CONTACT: Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that three petitions (FAP 9B4133, 9B4131, 9B4132) have been filed on behalf of The Lubrizol Corp., 29400 Lakeland Blvd., Wickliffe, OH 44092–2298. The petitions propose respectively that the food additive regulations in § 175.105 Adhesives (21 CFR 175.105), § 176.170 Components of paper and paperboard in contact with aqueous and fatty foods. (21 CFR 176.170), and § 176.180 Components of paper and

paperboard in contact with dry food (21 CFR 176.180) be amended to provide for the safe use of poly(sodium 2-acrylamido-2-methylpropanesulfonate) in adhesives and as components of paper and paperboard intended to contact food.

The potential environmental impact of this action is being reviewed. It the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: March 31, 1992.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-8027 Filed 4-7-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 92G-0129]

Weyerhaeuser Co.; Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Weyerhaeuser Co. has filed a petition (GRASP 2G0388) proposing that cellulose ($(C_6H_{10}O_5)_n$, an unbranched polymer of D-glucopyranose units joined by β=1,4-glucosidic bonds) derived by culturing *Acetobacter aceti* subspecies *xylinum* be affirmed as generally recognized as safe (GRAS) as a direct human food ingredient.

DATES: Written comments by June 8, 1992.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: F. Owen Fields, Center for Food Safety and Applied Nutrition (HFF-333), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-254-9523.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug and Cosmetic Act (secs. 201(s), 409(b)(5) (21 U.S.C. 321(s), 348(b)(5))) and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that Weyerhaeuser Co., Tacoma, WA 98477, has filed a petition (GRASP 2G0388) proposing that cellulose ($(C_6H_{10}O_5)_n$, an unbranched polymer of D-glucopyranose units joined by β=1,4-glucosidic bonds) derived by culturing *Acetobacter aceti* subspecies *xylinum* be affirmed as GRAS for use as a direct human food ingredient.

The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirments outlined in §§ 170.30 and 170.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Interested persons may, on or before June 8, 1992, review the petition and/or file comments (two copies, identified with the docket number found in brackets in the heading of this document) with the Dockets Management Branch (address above). Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. A copy of the petition and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 31, 1992.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 92-8028 Filed 4-7-92; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 92N-0160]

Fujisawa USA, Lyphomed Division; Withdrawal of Approval of One New Drug Application and Seven Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of one new drug application (NDA) and seven abbreviated new drug applications (ANDA's) held by Fujisawa USA, Lyphomed Division (Lyphomed), 2045 North Cornell Ave., Melrose Park, IL 60160. Lyphomed has agreed in writing to permit FDA to withdraw approval of the applications, and has waived its opportunity for a hearing. This action stems from the discovery of untrue statements, unresolved discrepancies, and omissions concerning information used to support approval of the application.

EFFECTIVE DATE: April 8, 1992.

FOR FURTHER INFORMATION CONTACT: Christina Good, Center for Drug Evaluation and Research (HFD-366), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-295-8041.

SUPPLEMENTARY INFORMATION: Recently, FDA became aware of untrue statements, discrepancies, and omissions that relate to manufacturing, control, and stability tests of drug products used to support approval of the following NDA and ANDA's held by Lyphomed:

NDA 18-507, Furosemide Injection, 10 milligrams per milliliter (mg/mL);

ANDA 70-058, Dopamine Hydrochloride Injection, 40 mg;

ANDA 70-059, Dopamine Hydrochloride Injection, 80 mg;

ANDA 70-071, Metronidazole Injection, 500 mg/100 mL;

ANDA 70-134, Bretylium Tosylate Injection, 50 mg/mL;

ANDA 70-295, Metronidazole Hydrochloride for Injection, 500 mg base/vial;

ANDA 70-364, Dopamine Hydrochloride Injection, 160 mg; and

ANDA 88-939, Leucovorin Calcium for Injection, 50 mg base/vial.

After careful review of inspectional findings, the agency determined that there was sufficient justification to initiate proceedings to withdraw approval of the products listed above. Lyphomed was notified in writing of these determinations on January 28, 1992, and, in accordance with 21 CFR 314.150(d), was offered an opportunity to permit FDA to withdraw the applications. Subsequently, in letters dated March 5, 1992, Lyphomed requested withdrawal of the NDA and the ANDA's, thereby waiving its opportunity for a hearing. During the time FDA was initiating the process for downgrading the therapeutic equivalence codes of the applications, Lyphomed specifically requested withdrawal of ANDA 88-939 in a letter dated February 10, 1992. FDA separately acknowledged receipt of this requested withdrawal of approval for ANDA 88-939 (Leucovorin Calcium for Injection, 50 mg base/vial) and stated that appropriate notice of withdrawal of